Merck & Co (NYSE: MRK) announced first-time results from the pivotal Phase 3 KEYNOTE-564 trial evaluating Keytruda for the potential adjuvant treatment in a subset of patients with renal cell carcinoma (RCC). The trial included RCC patients at intermediate-high or high risk of recurrence following nephrectomy (surgi
Full Story >>
Vote
+20